Biogen Inc (BUE:BIIB)
ARS 18434.5 -134.5 (-0.72%) Market Cap: 28.46 Til Enterprise Value: 33.64 Til PE Ratio: 27.65 PB Ratio: 2.11 GF Score: 53/100

Biogen Inc at Evercore HealthCONx Conference Transcript

Dec 03, 2019 / 04:45PM GMT
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Okay. So thank you all for being here. Anirvan, thank you for making time. Just to level set for everyone. I was talking to Joe and the Biogen team, and most of the folks on the Biogen side have flown out to CTAD. So first of all, thank you for -- Biogen for still making time. Thank you, Anirvan, for coming up.

Questions & Answers

Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Before we kick things off, Anirvan, since many of the investors on the street haven't had a chance to get to know you. Can you just tell us your role at the company, your background and also to level set how much we can or can't talk about aducanumab on this session?

Anirvan Ghosh
Biogen Inc. - SVP of Research and Early Development

Sure. Thanks for having me here. So just a couple of things. First of all, I might be making some forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot